Nachrichten zur Capricor Therapeutics Aktie

Capricor Therapeutics (CAPR): H.C. Wainwright bestätigt Kaufempfehlung mit 805 % Kurspotenzial - Panikreaktion könnte Einstiegsgelegenheit bieten!

Capricor Therapeutics (CAPR) ist ein aufstrebendes Biotechnologieunternehmen, das sich auf die Entwicklung transformativer Zell- und Exosomen-basierter Therapeutika zur Behandlung seltener…

Capricor Therapeutics stock plunges after key FDA officials placed on leave By Investing.com

Capricor Therapeutics stock plunges after key FDA officials placed on leave…

Capricor Therapeutics stock falls after FDA inspection of manufacturing facility By Investing.com

Capricor Therapeutics stock falls after FDA inspection of manufacturing facility…

Capricor Therapeutics (CAPR): Experten von Roth Capital sehen 192 % Kurspotenzial!

Capricor Therapeutics (CAPR) ist ein Biotechnologieunternehmen mit Fokus auf Zell- und Exosomen-basierte Therapien für seltene Krankheiten. Der Konzern hat am…

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - China Liberal Education (NASDAQ:CLEU), Capricor Therapeutics (NASDAQ:CAPR)

…

Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - China Liberal Education (NASDAQ:CLEU), Capricor Therapeutics (NASDAQ:CAPR)

…

Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript

…

Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates

Capricor (CAPR) delivered earnings and revenue surprises of 48.39% and 248.28%, respectively, for the quarter ended December 2024. Do the…

Capricor Therapeutics beats Q4 estimates, shares rise on FDA acceptance By Investing.com

Capricor Therapeutics beats Q4 estimates, shares rise on FDA acceptance…

Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data

…

Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript

…

Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates

Capricor (CAPR) delivered earnings and revenue surprises of -9.38% and 11.95%, respectively, for the quarter ended June 2024. Do the…

CORRECTION: Capricor Therapeutics

SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces…

Capricor Therapeutics files for $150M mixed shelf

…

Capricor Therapeutics stock rises, Oppenheimer initiates coverage at Outperform

…

Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript

…

Capricor Therapeutics Q1 2024 Earnings Preview

…

Ausblick: Capricor Therapeutics präsentiert Quartalsergebnisse

Capricor Therapeutics wird am 13.05.2024 die Geschäftsergebnisse zum jüngsten Jahresviertel vorstellen.Die Schätzungen von 3 Analysten gehen beim Ergebnis je Aktie…

Capricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcript

…

dpa-AFX ProFeed